Published in Clin Cancer Res on May 01, 2011
Targeting protein prenylation for cancer therapy. Nat Rev Cancer (2011) 2.60
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res (2012) 1.44
PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell Int (2015) 1.42
Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3β, pTSC2, and p4EBP1 by cotreatment with MK-2206. Biomed Res Int (2014) 1.41
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther (2011) 1.33
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res (2013) 1.09
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov (2012) 1.06
RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res (2012) 1.05
Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther (2013) 0.97
Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene (2013) 0.94
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res (2012) 0.90
Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation. Oncotarget (2014) 0.88
Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions. Curr Opin Chem Biol (2012) 0.87
Molecular targets for the treatment of juvenile myelomonocytic leukemia. Adv Hematol (2011) 0.83
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res (2013) 0.83
Cyclic marinopyrrole derivatives as disruptors of Mcl-1 and Bcl-x(L) binding to Bim. Mar Drugs (2014) 0.81
Mechanism underlying the inhibitory effect of Apelin-13 on glucose deprivation-induced autophagy in rat cardiomyocytes. Exp Ther Med (2013) 0.80
Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. Br J Cancer (2014) 0.80
Marinopyrrole derivatives with sulfide spacers as selective disruptors of Mcl-1 binding to pro-apoptotic protein Bim. Mar Drugs (2014) 0.76
Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex. J Cancer (2017) 0.75
Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem (1996) 8.08
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell (1988) 7.50
Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem (1998) 6.84
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol (2003) 4.53
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets (2008) 3.36
Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett (2009) 3.19
Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem (2003) 2.66
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
EGFR signaling and drug discovery. Oncology (2010) 2.53
Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer (2008) 2.39
Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res (2010) 2.30
Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res (2006) 2.05
Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer (2003) 1.67
Distinct biological roles for the akt family in mammary tumor progression. Cancer Res (2010) 1.62
Emerging targeted therapies for breast cancer. J Clin Oncol (2010) 1.61
Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev (2008) 1.60
GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest (2007) 1.47
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell (2005) 1.45
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem (2005) 1.43
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol (2008) 1.39
The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol (2000) 1.39
The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem (1997) 1.35
Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol Cell Biol (2007) 1.32
Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol (2002) 1.24
The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ (2010) 1.20
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs (2010) 1.16
Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol (2008) 1.15
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol (2009) 1.15
Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets (2007) 1.11
Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol Cancer Ther (2005) 1.10
Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist (2009) 1.05
Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials (2007) 1.04
Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res (2008) 1.01
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J Biol Chem (1999) 1.00
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res (2009) 1.00
Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J Clin Oncol (2006) 0.96
Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist (2010) 0.94
Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms. Curr Med Chem (2001) 0.92
The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ (2002) 0.91
Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. J Biol Chem (2000) 0.86
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol (2007) 8.29
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Label-free immunodetection with CMOS-compatible semiconducting nanowires. Nature (2007) 5.25
The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas (2010) 5.01
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol (2008) 4.45
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Retracted Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem (2002) 2.97
Detecting protein-protein interactions with a green fluorescent protein fragment reassembly trap: scope and mechanism. J Am Chem Soc (2005) 2.95
Retracted Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem (2003) 2.89
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70
Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed Engl (2005) 2.65
Targeting protein prenylation for cancer therapy. Nat Rev Cancer (2011) 2.60
Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril (2002) 2.48
Water gelation by small organic molecules. Chem Rev (2004) 2.45
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43
Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer (2009) 2.38
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood (2010) 2.37
Retracted MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem (2010) 2.34
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol (2005) 2.31
Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst (2008) 2.20
Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol (2004) 2.14
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem (2004) 2.11
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Synthetic non-peptide mimetics of alpha-helices. Chem Soc Rev (2007) 2.04
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem (2008) 1.98
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas (2010) 1.90
Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol (2012) 1.83
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther (2005) 1.75
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 1.72
Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol (2003) 1.72
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene (2005) 1.70
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
Immunohistochemical staining for c-Kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal Cancer (2002) 1.64
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res (2011) 1.64
Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer (2006) 1.64
Retracted Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem (2003) 1.63
EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer (2012) 1.63
p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res (2003) 1.62
Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol Biomarkers Prev (2010) 1.60
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.58
Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Angew Chem Int Ed Engl (2003) 1.55
Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J R Soc Interface (2006) 1.53
Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol (2011) 1.51
Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc (2002) 1.50
Retracted AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem (2003) 1.49
Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl (2005) 1.49
Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One (2009) 1.48
Retracted IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem (2011) 1.47
Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. Curr Opin Chem Biol (2010) 1.47
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl (2002) 1.47
Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. J Am Chem Soc (2005) 1.46
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem (2002) 1.43
Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem (2005) 1.42
Strategies for profiling microRNA expression. J Cell Physiol (2009) 1.41
Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One (2010) 1.41
Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol (2004) 1.40
The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem (2010) 1.39
Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2006) 1.38
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Am Chem Soc (2006) 1.36
IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther (2002) 1.36